CYTOKINETICS INCORPORATED - COMMON STOCK

Cytokinetics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

05 Feb 2025 16:00:00 By Nasdaq GlobeNewswire

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 Feb 2025 16:00:00 By Nasdaq GlobeNewswire

Cytokinetics Announces Recipients of Its Seventh Annual Communications Grant Program

30 Jan 2025 07:30:00 By Nasdaq GlobeNewswire

Cytokinetics Announces Start of AMBER-HFpEF, a Phase 2 Clinical Trial of CK-586 in Patients With Symptomatic Heart Failure With Preserved Ejection Fraction

21 Jan 2025 07:30:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: CYTOKINETICS INCORPORATED - COMMON STOCK

13 Jan 2025 14:43:22 By NetDania Notify

Cytokinetics Announces 2025 Corporate Milestones and Vision 2030

13 Jan 2025 07:30:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: CYTOKINETICS INCORPORATED - COMMON STOCK

10 Jan 2025 10:28:43 By NetDania Notify

Cytokinetics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

06 Jan 2025 16:00:00 By Nasdaq GlobeNewswire

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

03 Jan 2025 16:00:00 By Nasdaq GlobeNewswire

Cytokinetics Announces European Medicines Agency Validation of Marketing Authorization Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy

23 Dec 2024 07:30:00 By Nasdaq GlobeNewswire

Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China

20 Dec 2024 00:00:00 By Nasdaq GlobeNewswire

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 Dec 2024 16:00:00 By Nasdaq GlobeNewswire

Cytokinetics Announces Start of COMET-HF, a Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Symptomatic Heart Failure with Severely Reduced Ejection Fraction

03 Dec 2024 07:30:00 By Nasdaq GlobeNewswire

Cytokinetics to Participate in December Investor Conferences

02 Dec 2024 16:00:00 By Nasdaq GlobeNewswire

Cytokinetics Announces FDA Acceptance of New Drug Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy

02 Dec 2024 07:30:00 By Nasdaq GlobeNewswire

Cytokinetics and Bayer Announce Exclusive Licensing Collaboration for Aficamten in Japan

19 Nov 2024 02:30:00 By Nasdaq GlobeNewswire

Cytokinetics Presents New Data Relating to Aficamten and Hypertrophic Cardiomyopathy at the American Heart Association Scientific Sessions 2024

16 Nov 2024 09:00:00 By Nasdaq GlobeNewswire

Cytokinetics Presents Additional Data From GALACTIC-HF at the American Heart Association Scientific Sessions 2024

16 Nov 2024 09:00:00 By Nasdaq GlobeNewswire

Cytokinetics to Participate in the 2024 Jefferies London Healthcare Conference

12 Nov 2024 16:00:00 By Nasdaq GlobeNewswire

Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-4015089

11 Nov 2024 07:30:00 By Nasdaq GlobeNewswire